Form 4: FibroGen Director Maykin Ho Acquires 70,000 Stock Options
SEC Form 4 Filing
Director Maykin Ho acquired 70,000 stock options in FibroGen, Inc. on June 5, 2024, according to a Form 4 filing.
Summary
- On June 5, 2024, Maykin Ho, a director of FibroGen, Inc., acquired 70,000 stock options.
- The exercise price of these options is $1.21.
- The options vest on the earlier of June 16, 2025, or the date of the next annual meeting of stockholders, contingent upon continuous service.
- The options expire on June 4, 2034.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard disclosure of stock option acquisition by a director, which is a common part of executive compensation.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: Maykin Ho acquired 70,000 stock options. |
| 06/16/2025 | Earliest vesting date for the options, contingent upon continuous service. |
| 06/04/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.